<SEC-DOCUMENT>0001193125-22-265755.txt : 20221020
<SEC-HEADER>0001193125-22-265755.hdr.sgml : 20221020
<ACCEPTANCE-DATETIME>20221020091208
ACCESSION NUMBER:		0001193125-22-265755
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20221020
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221020
DATE AS OF CHANGE:		20221020

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		221320046

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d414605d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20221020" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2022-10-20_to_2022-10-20">AMGEN INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-10-20_to_2022-10-20">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-10-20_to_2022-10-20">0000318154</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="amgn-20221020.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-10-20_to_2022-10-20"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-20</xbrli:startDate> <xbrli:endDate>2022-10-20</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-20</xbrli:startDate> <xbrli:endDate>2022-10-20</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-20</xbrli:startDate> <xbrli:endDate>2022-10-20</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&#160;</p> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-10-20_to_2022-10-20">8-K</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d) of</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Date of Report (Date of earliest event reported)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-10-20_to_2022-10-20" format="ixt:datemonthdayyearen">October 20, 2022</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Amgen Inc.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-10-20_to_2022-10-20" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-10-20_to_2022-10-20">001-37702</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-10-20_to_2022-10-20">95-3540776</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction of<br />incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-10-20_to_2022-10-20">One Amgen Center Drive</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-10-20_to_2022-10-20">Thousand Oaks</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-10-20_to_2022-10-20" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-10-20_to_2022-10-20">91320</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-10-20_to_2022-10-20">(805)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-10-20_to_2022-10-20">447-1000</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top">&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-10-20_to_2022-10-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top">&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-10-20_to_2022-10-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top">&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-10-20_to_2022-10-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top">&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-10-20_to_2022-10-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common stock, $0.0001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember">2.000% Senior Notes due 2026</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember">AMGN26</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-10-20_to_2022-10-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&#160;</p> <p style="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;20, 2022, Amgen Inc. issued a press release announcing the completion of its previously announced acquisition of ChemoCentryx, Inc. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in this Item 7.01 and Exhibit 99.1 shall not be deemed to be &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Exhibit<br />No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Description of Exhibit</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d414605dex991.htm">Press Release, dated as of October&#160;20, 2022 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">AMGEN INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:24pt"></td>
<td style="height:24pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="text-decoration:underline">/s/ Jonathan P. Graham&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Name: Jonathan P. Graham</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Title: Executive Vice President, General Counsel and Secretary</td></tr>
</table></div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October&#160;20, 2022 </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d414605dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g414605g1019081341130.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:18pt; font-family:ARIAL"><B><I>News Release</I></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One Amgen Center Drive</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thousand Oaks, CA 91320-1799</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Telephone <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-1000</FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;www.Amgen.com</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>TAVNEOS<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;(avacopan), a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT> Medicine for Patients </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>With Severe Active
ANCA-Associated Vasculitis, Added to </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Inflammation Portfolio </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">THOUSAND OAKS, Calif., (Oct. 20,&nbsp;2022) &#150; Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced
acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger
consideration of approximately $3.7&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">&#147;ChemoCentryx enhances Amgen&#146;s leading inflammation and nephrology portfolio and
includes TAVNEOS<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (avacopan), a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> treatment for severe active anti-neutrophil cytoplasmic
autoantibody-associated vasculitis (ANCA-associated vasculitis), an autoimmune disease for which there remains significant unmet medical need,&#148; said Robert A. Bradway, chairman and chief executive officer at Amgen. &#147;We look forward to
welcoming the dedicated professionals from ChemoCentryx who share our passion for advancing innovation that makes a difference for patients. Together, we aim to serve more patients affected by serious diseases.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">The acquisition includes TAVNEOS<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, an orally administered selective complement 5a receptor
inhibitor that was approved by the U.S. Food and Drug Administration (FDA) in October 2021 as an adjunctive therapy for adults with severe active ANCA-associated vasculitis in addition to standard of care, which generally consists of glucocorticoids
and either rituximab or cyclophosphamide immunosuppressant therapy. Beyond its approved ANCA-associated vasculitis indication, TAVNEOS<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is also being studied in additional inflammatory
diseases, including hidradenitis suppurativa (HS), a severe and deforming chronic dermatological condition, and complement 3 glomerulopathy (C3G), a rare genetic kidney disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">In addition to TAVNEOS<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, the acquisition adds three early-stage drug candidates that target
chemoattractant receptors and other inflammatory diseases and an oral checkpoint for cancer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Page 2 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>About Amgen</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically
improve people&#146;s lives. A biotechnology pioneer since 1980, Amgen has grown to be&nbsp;one of&nbsp;the world&#146;s&nbsp;leading&nbsp;independent biotechnology companies, has reached millions of patients around the world and is developing a
pipeline of medicines with breakaway potential.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of
the <FONT STYLE="white-space:nowrap">Nasdaq-100</FONT> index. In 2021, Amgen was named one of the 25 World&#146;s Best Workplaces<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> by Fortune and Great Place to Work<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> and one of the 100 most sustainable companies in the world by Barron&#146;s. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">For more
information, visit&nbsp;www.amgen.com&nbsp;and follow us on&nbsp;www.twitter.com/amgen.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>About&nbsp;ChemoCentryx </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">ChemoCentryx&nbsp;is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and
cancer.&nbsp;ChemoCentryx&nbsp;targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. In&nbsp;the United States,&nbsp;ChemoCentryx&nbsp;markets TAVNEOS<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;(avacopan), the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis.
TAVNEOS is also in late-stage clinical development for the treatment of severe hidradenitis suppurativa and C3 glomerulopathy (C3G). Additionally,&nbsp;ChemoCentryx&nbsp;has early-stage drug candidates that target chemoattractant receptors in other
inflammatory and autoimmune diseases and in cancer. For more information about&nbsp;ChemoCentryx&nbsp;visit&nbsp;www.chemocentryx.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>About</B><B></B><B>&nbsp;TAVNEOS</B><B><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></B><B></B><B>&nbsp;(avacopan)</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">TAVNEOS (avacopan), approved by the FDA as an adjunctive treatment of ANCA-associated vasculitis, is a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class,</FONT></FONT> orally administered small molecule that employs a novel, highly targeted mode of action in complement-driven autoimmune and inflammatory diseases. While the precise mechanism in ANCA
vasculitis has not been definitively established, TAVNEOS, by blocking the complement 5a receptor (C5aR) for the <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> complement system fragment known as C5a on destructive inflammatory cells such
as blood neutrophils, is presumed to arrest the ability of those cells to do damage in response to C5a activation, which is known to be the driver of ANCA vasculitis. TAVNEOS&#146;s selective inhibition of only the C5aR leaves the beneficial C5a
pathway through the C5L2 receptor functioning normally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">ChemoCentryx&nbsp;is also developing TAVNEOS for the treatment of patients with C3
glomerulopathy (C3G), severe hidradenitis suppurativa (HS) and lupus nephritis (LN). The&nbsp;U.S. Food and Drug Administration&nbsp;granted TAVNEOS orphan drug designation for ANCA-associated vasculitis and C3G. The&nbsp;European
Commission&nbsp;has granted orphan medicinal product designation for TAVNEOS for the treatment of two forms of ANCA-associated vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener&#146;s
granulomatosis), as well as for C3G. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Page 3 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>About ANCA-Associated Vasculitis </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">ANCA-associated vasculitis is an umbrella term for a group of multi-system autoimmune diseases with small vessel inflammation. Inflamed vessels may
rupture or become occluded giving rise to a broad array of clinical symptoms and signs related to a systemic inflammatory response which may result in profound injury and dysfunction in the kidneys, lungs and other organs. Prior to the approval of
TAVNEOS, treatment for ANCA-associated vasculitis was limited to courses of <FONT STYLE="white-space:nowrap">non-specific</FONT> immuno-suppressants (cyclophosphamide or rituximab), combined with the administration of daily glucocorticoids
(steroids) for prolonged periods of time, which can be associated with significant clinical risk including death from infection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>U.S.&nbsp;PRESCRIBING
INFORMATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">TAVNEOS (avacopan) is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic
autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">IMPORTANT SAFETY INFORMATION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Contraindications </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Serious hypersensitivity to avacopan or to any of the excipients </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Warning and
Precautions </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Hepatotoxicity: Serious cases of hepatic injury have been observed in patients taking TAVNEOS, including life-threatening events.
Obtain liver test panel before initiating TAVNEOS, every 4 weeks after start of therapy for six months and as clinically indicated thereafter. Monitor patients closely for hepatic adverse reactions, and consider pausing or discontinuing treatment as
clinically indicated (refer to section 5.1 of the Prescribing Information). TAVNEOS is not recommended for patients with active, untreated and/or uncontrolled chronic liver disease (e.g., chronic active hepatitis B, untreated hepatitis C,
uncontrolled autoimmune hepatitis) and cirrhosis. Consider the risk and benefit before administering this drug to a patient with liver disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Serious Hypersensitivity Reactions: Cases of angioedema occurred in a clinical trial, including one serious event requiring hospitalization. Discontinue
immediately if angioedema occurs and manage accordingly. TAVNEOS must not be <FONT STYLE="white-space:nowrap">re-administered</FONT> unless another cause has been established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Hepatitis B Virus (HBV) Reactivation: Hepatitis B reactivation, including life threatening hepatitis B, was observed in the clinical program. Screen
patients for HBV. For patients with evidence of prior infection, consult with physicians with expertise in HBV and monitor during TAVNEOS therapy and for six months following. If patients develop HBV reactivation, immediately discontinue TAVNEOS and
concomitant therapies associated with HBV reactivation, and consult with experts before resuming. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Serious Infections: Serious infections, including
fatal infections, have been reported in patients receiving TAVNEOS. The most common serious infections reported in TAVNEOS group were pneumonia and urinary tract infections. Avoid use of TAVNEOS in patients with active, serious infection, including
localized infections. Consider the risks and benefits before initiating TAVNEOS in patients with chronic infection, at increased risk of infection or who have been to places where certain infections are common. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Adverse Reactions </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">The most common adverse reactions (<FONT STYLE="font-family:Times New Roman">&#8805;</FONT>5% of patients and higher in the TAVNEOS group vs. prednisone
group) were: nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, blood creatinine increased, and paresthesia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Drug
Interactions </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Avoid coadministration of TAVNEOS with strong and moderate CYP3A4 enzyme inducers. Reduce TAVNEOS dose when <FONT
STYLE="white-space:nowrap">co-administered</FONT> with strong CYP3A4 enzyme inhibitors to 30 mg once daily. Monitor for adverse reactions and consider dose reduction of certain sensitive CYP3A4 substrates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Please see&nbsp;Full Prescribing Information&nbsp;and&nbsp;Medication Guide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Amgen Forward-Looking Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">This news release contains
forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the
outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd., Kyowa-Kirin Co., Ltd., or any collaboration to manufacture therapeutic antibodies against
<FONT STYLE="white-space:nowrap">COVID-19),</FONT> the performance of Otezla<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (apremilast) (including anticipated Otezla sales growth and the timing of
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> EPS accretion), the Five Prime Therapeutics, Inc. acquisition, the Teneobio, Inc. acquisition, or the ChemoCentryx, Inc. acquisition (including the prospective performance and outlook of
ChemoCentryx&#146;s business, performance and opportunities and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash,
other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health
problems such as the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business, and other such estimates and results.&nbsp;Forward-looking statements involve significant risks and uncertainties, including those discussed
below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and any subsequent periodic reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> and current reports on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to
update any forward-looking statements contained in this document as a result of new information, future events or otherwise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"> Page
 5
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">No forward-looking statement can be guaranteed and actual results may differ materially from those we
project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched
products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny
and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward
managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify
safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may
be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to
significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to
prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our
manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the
distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations.
We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our
marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product
is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices
and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product
similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other
companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic
benefits, synergies or opportunities arising from the ChemoCentryx acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate ChemoCentryx, and such integration
may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may
be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related
natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a
dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"> Page
 6
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">CONTACT: Amgen, Thousand Oaks</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Jessica Akopyan, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-440-5721</FONT></FONT> (media)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Megan Fox, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-1423</FONT></FONT> (media) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Arvind Sood, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-1060</FONT></FONT> (investors)</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>amgn-20221020.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 10/20/2022 4:59:50 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:amgn="http://www.amgen.com/20221020"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.amgen.com/20221020"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20221020_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20221020_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20221020_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="amgn_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="amgn_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>amgn-20221020_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 10/20/2022 4:59:53 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20221020.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="amgn-20221020.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="amgn-20221020.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="amgn_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeniorNotesMember" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>amgn-20221020_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 10/20/2022 4:59:50 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="amgn-20221020.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="amgn_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="amgn-20221020.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="amgn_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotesMember" xlink:to="us-gaap_SeniorNotesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeniorNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Senior Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeniorNotesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior Notes [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>amgn-20221020_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 10/20/2022 4:59:51 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20221020.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="amgn-20221020.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="amgn_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="amgn-20221020.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="amgn_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeniorNotesMember" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g414605g1019081341130.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g414605g1019081341130.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% ,L# 2(  A$! Q$!_\0
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M-/[S'H*^?;Z^N-2O9;RZD,DTK;F8_P OI7'@<'[9\T_A7XG?F./^KKDA\3_
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MH1Q?8[<0DF,G<1WZU+KX6-2,H66]]/(M8;&SI3C4N[VM=^?J>;>$?^1NTO\
MZ[BO4OB7HZZCX::\1?W]D=X/^R>&'\C^%96C?#"YTO6;2_;5(I%@D#E!$03^
MM>A7MLM[87%J_P!V:-HSQZC%<^*Q4'7A4IN]CIP6#FL/.E55KGS-7M7PM_Y%
M#_MX?^E<]_PJ&[_Z"\/_ 'Y/^-=UX2T"3PWHWV"2X6=O,9]ZKM'-:X_%4JM+
ME@[NYCEN#KT:W-.-E8W:***\4]\**** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140080349997904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 20, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMGEN INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 20,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">2.000% Senior Notes due 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d414605d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amgn-20221020.xsd" xlink:type="simple"/>
    <context id="duration_2022-10-20_to_2022-10-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2022-10-20</startDate>
            <endDate>2022-10-20</endDate>
        </period>
    </context>
    <context id="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-20</startDate>
            <endDate>2022-10-20</endDate>
        </period>
    </context>
    <context id="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-20</startDate>
            <endDate>2022-10-20</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2022-10-20_to_2022-10-20"
      id="Hidden_dei_EntityRegistrantName">AMGEN INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2022-10-20_to_2022-10-20">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-10-20_to_2022-10-20"
      id="Hidden_dei_EntityCentralIndexKey">0000318154</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-10-20_to_2022-10-20">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-10-20_to_2022-10-20">2022-10-20</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-10-20_to_2022-10-20">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-10-20_to_2022-10-20">001-37702</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-10-20_to_2022-10-20">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-10-20_to_2022-10-20">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-10-20_to_2022-10-20">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-10-20_to_2022-10-20">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-10-20_to_2022-10-20">91320</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-10-20_to_2022-10-20">(805)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-10-20_to_2022-10-20">447-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-10-20_to_2022-10-20">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-10-20_to_2022-10-20">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-10-20_to_2022-10-20">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-10-20_to_2022-10-20">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember">2.000% Senior Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-10-20_to_2022-10-20_us-gaap-StatementClassOfStockAxis_us-gaap-SeniorNotesMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-10-20_to_2022-10-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M@TE45;EQ7.*[!   ,Q4  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RU
MF'%OXC88QK^*E=VF36I+XD"A'2!1VM[072E7V$[::7^8Q(#5),YLI[3??J\3
MFG"[\ 95:J6V"<0/O_CU^SPF_:U4CWK#N2'/<93H@;,Q)KULM72PX3'39S+E
M";RSDBIF!D[5NJ53Q5F8#XJC%G7=\U;,1.(,^_EK,S7LR\Q$(N$S1706QTR]
M7/%(;@>.Y[R^\"#6&V-?: W[*5OS.3=_IC,%9ZU2)10Q3[20"5%\-7!&WN65
MGP_(K_A+\*W>.R;V5I92/MJ323AP7$O$(QX8*\'@WQ,?\RBR2L#Q[T[4*3_3
M#MP_?E6_S6\>;F;)-!_+Z*L(S6;@]!P2\A7+(O,@MW_PW0UUK%X@(YW_)=OB
MVG;'(4&FC8QW@X$@%DGQGSWO)F)O@$\/#*"[ 33G+CXHI[QFA@W[2FZ)LE>#
MFCW(;S4?#7 BL569&P7O"AAGAM<RR&"2#6%)2&X2(\P+F21%M6'6^BT#'V(O
M;04[P:M"D!X0O _,&:'N"?Q2^OWP%K"5@+0$I+F>WP0XJ@4DWS[# #(Q/-;_
MU-$6ZNUZ=;OF+W7* CYP8%%KKIZX,_SE)^_<_1UA]TMV'U,?[G ?^%IHHQC<
MQ)3%O(X2UQG=?;R9DLETC#"U2Z8VK@63&>83>ANQ=1T+/G[%(LT1CD[)T3EF
M;L9 HE@$)0WY,_G$7^J(<"47?GROYW7:"-9YB76.BI7+;?&2UE8*']X[_81
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( (-)5%4<.&7J/P$  #P"   /
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MDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " "#2515)!Z;HJT   #X 0
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I
M0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LID
MR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\
M./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6
M?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ @TE45660>9(9 0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( (-)5%5ZW\"U[0   "L"   1
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M96QS+RYR96QS4$L! A0#%     @ @TE451PX9>H_ 0  / (   \
M     ( !PA   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( (-)5%4D'INB
MK0   /@!   :              "  2X2  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( (-)5%5ED'F2&0$  ,\#   3
M  "  1,3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  %T4
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d414605d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  d414605d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d414605d8k.htm">d414605d8k.htm</File>
    <File>amgn-20221020.xsd</File>
    <File>amgn-20221020_def.xml</File>
    <File>amgn-20221020_lab.xml</File>
    <File>amgn-20221020_pre.xml</File>
    <File>d414605dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d414605d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "amgn-20221020_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d414605d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20221020_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20221020_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "amgn-20221020.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 2,
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20221020",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d414605d8k.htm",
      "contextRef": "duration_2022-10-20_to_2022-10-20",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d414605d8k.htm",
      "contextRef": "duration_2022-10-20_to_2022-10-20",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "amgn_DocumentAndEntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationLineItems",
     "nsuri": "http://www.amgen.com/20221020",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_DocumentAndEntityInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationTable",
     "nsuri": "http://www.amgen.com/20221020",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.amgen.com//20221020/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-22-265755-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-265755-xbrl.zip
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M# W;>?P@R#2">=RJ[#C8'$-.C '"Q-V:7HNUW#KPG1,C)X>["!$KTRXS@\!
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M7Q PS_BKA%F7N#Y4X?%?4$L#!!0    ( (-)5%78$/\GP@4  "LT   5
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MKF^'#\A'"Z52V0V"U6K5B&>$24Z72H>4C8@G ?)]6W\P^8C^V#;714]  4M
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MYWIBJ/*3F5N>YT[S' /3N3]P!;(^SQ*Q(SQ+,K<\.]\ S]<7Z-MSS1/,B5E
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M<Q6!,:)NP/)$2$O G8%^CP$80$]DE(MQ9N*&K<.6C#4B4V8BE?0H;5:&,]!
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MNCN/&CG06.O>FOYU\*+=6I]:_9(;Q 0O!\UE"KR6"GQ<O#H]V\($A U,OU@
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M)WS8:]@)LFD?1RE1Z8X9R"D0E+@GKH(,!$'),39AM&=8#]<1FH:M9F MV+.
MR2;B_17Y[! \(;=BHC-=Y)AY2]POJX8+6 B,SD=OP3#D/AAWZ@YBN;K:@%DN
MML+#$&QY^2Y7E,.!EV3EJ6"-E:J:BRN&)L$&YJ+NX,2R]#(M7QW<@7*U:]YE
M[I"#DJFTV*=QMPX)ANY0\MKE5@?E]WBV6V-9<#-H]67M@S.%_?Q+/AA3I1RU
M6A%2/H[+^^@3P*'D*U,VAG*BY[A[CLP[!;J-RL 5.-0&"1Z8"F/>*#W1GUF.
MB@I8N:3D#O>SLH[&SB,34-TV;,RPXA%RWR7D=].&U64X%^9-CRU%28#M2C M
M^1O81_6]H#9_XYT N!AN]H#/44X!:!>R&4^RV"/+<O\[Z?<72/H)ROK!=E_B
MEO_4J;^^9:D5S7C*^Q(^WJS09;'9( O^D-<:^_?.U%Q<0F2>8-_2JU?;NV\L
M6]C]OMD$!Z:/14IJIR9(:(+7#! C!:X!G -8$J;FX=,MPK0]D2#3D!UL'@RQ
MT:[#P6&!# W! -P2$%%\8H;.AQI#,[I*!J"L)R42Z!0OFLE1B-=KT&F#\>,/
M?_L-^^P K+F*AX@"O\<^E@I>V#NE$FMX4Y5K^5C9(2S[M%M#-&=?#YZ@S8^<
M06!6TW/ND&R>!&!X8OD&7<!38O#SQ8O^2Z&2WQ8QRBPL 5GA+"\5_LE+EU#N
M%(#X 37RP*REG_X:EJ>UK3542'VQ+6+DVC ]91?K4-%>B%I2\49 2 O-</%.
M!,Y3N'B@VG->CDA4*G^T/,\%O0(%IK9ENN,RBNX*+:L^.O[#AZKK2YR4L+5'
M6R.B/[5>'O-%MNZI,91<H)ZL^-O<9GXXH&%8C:^/R?CU,7BR>'P0Q-N+=MW(
MKB^OUT=-%>C_1])>@"6&CT$=$%GDHD$A:VT9J4BK,=<O^4I?'\ZE'J]C$_L%
M5DN]::BQ.@=-I+@!V]8[-.OR2@)38O\FW@!4,><%[EBY'\)@-LR?C#;1;ME6
MZT[-O*CRL4@4")Q#V0!B 3DR;/:X^LQKVU_^DHDA9MXX"K2-B)OU0@Z4/H&Y
M.N*T"'L=\=/"S&7W)PQS@13VW,=HB]3 Z V/YEMW]+OK;-3S*&RNF.*)"9YH
M\8"K^8/S3\/#[L[KK4YU(Q4[651&9F/CK_-"_1;)K[I2"ZX+U%+FQ98O"%QR
MH%,*?'@2D4N(H:DQG:3(;>&%I@M?6.EY4'7FI-^_</LYNKC"B#]3E%[B;L1C
M1*F+#!PT1A35A0=[)=R[,L6/7\-AF9$VZ[ZW!?PU-\O]FU?>GKE3R& !B<#2
MES65O,J"KKWB9AM]&K8U980).?+(*[],4^JTYNL5?/W*:XD7#,834!6GZ1U?
MS;.E =BJ;97#5?.PL[$,IO[FFFT!P 'HHCG9389)G!(O 9B4[J/#_AG'X*-
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M   1              "  0    !A;6=N+3(P,C(Q,#(P+GAS9%!+ 0(4 Q0
M   ( (-)5%78$/\GP@4  "LT   5              "  1H$  !A;6=N+3(P
M,C(Q,#(P7V1E9BYX;6Q02P$"% ,4    " "#25156(=._+D'  #L50  %0
M            @ $/"@  86UG;BTR,#(R,3 R,%]L86(N>&UL4$L! A0#%
M  @ @TE45<"1XYQV!0  KC<  !4              ( !^Q$  &%M9VXM,C R
M,C$P,C!?<')E+GAM;%!+ 0(4 Q0    ( (-)5%5O55#90 \   YC   .
M          "  :07  !D-#$T-C U9#AK+FAT;5!+ 0(4 Q0    ( (-)5%4H
M$6F()!\  ,)O   1              "  1 G  !D-#$T-C U9&5X.3DQ+FAT
7;5!+!08     !@ & (,!  !C1@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
